Dysplasia and carcinoma-in-situ are generally considered to be preinvasive conditions of squamous cell carcinoma of the uterine cervix (Harris et al., 1980; Murphy & Coleman, 1976; Noda et al., 1976; Shingleton et al., 1968) . A minority of these patients develop invasive squamous cell carcinoma when not treated (Noda et al., 1976) . Diagnostic methods to detect which lesions will progress to invasive carcinoma are not available.
Immunosurveillance may be one of the mechanisms which determine the progressive potential of preinvasive lesions (Cochran, 1978; DiSaia et al., 1972; loachim, 1976; Moore, 1978) . This prompted us to investigate immune reactivity to antigens of cervical carcinoma cells in patients with invasive and preinvasive stages of cervical carcinoma. We previously reported on the occurrence of antibodies directed to cervical carcinoma cells. These antibodies were mainly found in patients with macroinvasive stages of the tumour ( Van de Linde et al., 1981) . Cellular immune reactivity against antigens of cervical carcinoma cells has been described in patients with invasive disease (Cerni et al., 1979; Chen et al., 1975; Chiang et al., 1976; DiSaia et al., 1972; Goldstein et al., 1971; Mashiba et al., 1977; Pattillo et al., 1977; Rivera et al., 1979; Wells et al., 1973 0007-0920/83/010147-07 $01.00
However, data in patients with dysplasia and carcinoma-in-situ are conflicting (Chiang et al., 1976; Mashiba et al., 1977; Rivera et al., 1979) .
In this study we investigated the presence of cellular immune reactivity to cervical carcinoma cells both in patients with microinvasive cervical carcinoma and in preinvasive disease. Furthermore we looked for a relationship between the presence of cell-mediated immune reactivity and of serum antibodies.
Materials and Methods

Patients
Blood was obtained from patients with macroinvasive and preinvasive stages (i.e. carcinoma-in-situ and dysplasia) of carcinoma of the uterine cervix. All invasive tumours were classified histologically as squamous cell carcinoma and staged according to the principles of the FIGO. In all patients with preinvasive stages, cytology and colposcopy was performed and the diagnosis was confirmed histologically. None of the patients received any form of treatment before the time of blood sampling. The number of patients, median age and age range for each group are given in Table I .
Female patients with tumours other than squamous cell carcinoma of the uterine cervix served as controls; the tumours of these patients were adenocarcinoma of the uterine cervix (5), adenocarcinoma of the uterine corpus (3), carcinoma of the colon (3), carcinoma of the breast Cervical carcinoma cell lines used for this study were the ME-180 cell line (Sykes et al., 1970) and the CaSki cell line (Pattillo et al., 1977) . Cultured cells from the breast carcinoma cell line MCF-7 (Soule et al., 1973) , from skin fibroblast cultures and from amnion epithelial cells (all of human origin)
were used as controls.
Cells were cultured in 175 cm2 plastic flasks (Falcon) or 850cm2 plastic roller bottles (Falcon); the culture medium consisted of Minimal Essential Medium with Earle's salts (Gibco) buffered with 25mM HEPES and supplemented with 10% heat-inactivated foetal calf serum (Gibco), 2mM glutamine (Gibco), 100 I.Ul. ml-' penicillin and 100 ug ml-' streptomycin.
Antigen preparation Cell membrane antigen preparations were prepared according to Patillo et al. (1977) . Cells were subcultured in PBS supplemented with 0.25% trypsin 1:250 (Serva) and 0.5mM EDTA (Hayflick, 1973) . Two or 3 days after subculturing the cells were washed 3x in RPMI 1640 (Gibco) buffered with 25mM HEPES and subsequently incubated in this medium. After 24 h, the culture fluid was removed and centrifuged (10min, 2500g) to remove non-adherent cells and cell-debris. The supernatant was concentrated by membrane ultrafiltration under nitrogen pressure (Amicon, YM1O membrane, exclusion limit 10,000 dalton), centrifuged at 45,000g for 15min, sterilized by membrane filtration (0.22pm, Millipore) and stored in small aliquots at -30°C. After acid precipitation (Patt & Grimes, 1974 ) the protein content was measured by the Folin method (Oyama & Eagle, 1956 Cultures were set up in round bottomed microtiter plates (Nunc) and contained 50 ,ul antigen preparation and 100 4l cell suspension (final cell concentration 1.3 x 106 ml-1). Cell cultures were incubated for 6 days at 37'C in humidified air with 5% CO2. Tumour and control antigens were used in 3 different concentrations (100, 50 and 25 pgml-' final concentration). Sixteen-18h before the end of the incubation period 1 pCi (methyl-3H)-thymidine (5 Ci mM, Radiochemical Centre, Amersham) was added to each well. The cells were collected on Titertek glass-fiber filters with a semi-automatic harvester (Skatron). Air-dried filters were placed in scintillation vials and 3ml toluene scintillator was added. Radioactivity was measured with a Nuclear Chicago Liquid Scintillation Counter (NC 725). Stimulation with the T cell mitogen phytohaemagglutinin (PHA; HA15, Wellcome, 40 pgml-1 final concentration), and recall-antigens candidine (Haarlem Allergen Laboratory, Haarlem, the Netherlands, 10 pg ml-1 final concentration) and varidase (Lederle, 2 pg ml-' final concentration), was performed in each culture as control for reactivity of the mononuclear cells. Results were expressed as the mean counts per minute (cpm) of quadruplicate cultures and as stimulation index (SI = cpm of tumour antigenstimulated cultures . cpm of control antigenstimulated cultures). Data for optimal lymphocyte stimulation are given; this was obtained for one of the 3 antigen concentrations. The mean SI for groups of patients is given in the text as a geometric mean value.
Tumour-directed antibody Antibodies to the cell membrane of ME-180 cervical carcinoma cells were determined by indirect immunofluorescence as described previously (Van de Linde et al., 1981) . Sera were considered positive if the observed fluorescence remained after absorption with pooled human tonsillar lymphocytes.
Statistical analysis
The Kolmogorov-Smirnov one-sample test and the Chi-square test were used.
Results
For the group of patients with macroinvasive squamous cell carcinoma of the uterine cervix, data (cpm) from stimulation of individual lymphocyte preparations with antigen from the CaSki cell line (optimal stimulation), antigen from amnion epithelial cells and PHA are presented in Table II .
Antigen preparations of the ME-180 cell line gave high cpm values in both patients and controls Positive stimulation with PHA was observed in all individuals tested; cpm data are given in Table II for the group of macroinvasive cervical carcinoma patients. In this group the geometric mean SI was 66 and the range, 16-590. In the group of patients with carcinoma-in-situ or dysplasia the geometric SI after PHA stimulation was 72 (range, 30-1244), in the group of patients with other tumours, 43 (2-260) and in the control group, 63 (22-151). In a similar way, the various groups of patients and controls did not differ in responsiveness to recallantigens candidine and varidase (data not shown). There was no relation between the magnitude of the response after mitogenic or recall-antigenic stimulation and after CaSki carcinoma antigen stimulation, being either expressed as cpm or as SI.
The results (SI) of the individual lymphocyte cultures with CaSki cervical carcinoma antigen are shown in Figure 1 . In the control group of healthy donors, the SI values were normally distributed (Kolmogorov-Smirnov one-sample test). The arithmetic mean SI +s.e. was 3.2+0.5 and the 95% confidence interval, 2.3-4.1. From these data a stimulation index of 4.1 or higher was considered to be positive. In Table I the frequency of positive lymphocyte stimulation in the various patient groups is given.
Cultures from 8/19 (42%) patients with macroinvasive cervical carcinoma were positive. In the group of patients with other tumours 5/20 (25%) patients were positive. There was no obvious association between positive stimulation and a particular tumour. Highest individual stimulation indices were found in the group of mild-tomoderate dysplasia patients (Figure 1) . Also, the highest frequency (88%) of positive lymphocyte stimulation was observed in this group and was significantly higher than that in patients with macroinvasive disease (42%), and both control groups (P<0.01).
All patients and controls tested in the lymphocyte stimulation assay were simultaneously assessed for the presence of serum antibody. Data on the relation with lymphocyte stimulation are graphically presented in Figure 2 . The frequency of either positive lymphocyte stimulation or circulating antibodies was 64% in patients with advanced and 61% with early macroinvasive carcinoma, 59% with carcinoma-in-situ/severe dysplasia, 75% with mildto-moderate dysplasia, 25% in patients with other tumours and 16% in the control donor group, respectively. Both cellular immune reactivity as well as serum antibody were detectable in 36% of patients with advanced and 26% with early macroinvasive cervical carcinoma, 16% with carcinoma-in-situ/severe dysplasia, 14% with mild to moderate dysplasia, and 5-6% of patients with other tumours and the control donor group.
Discussion
In this study a lymphocyte stimulation assay with the concentrated serum-free culture supernatant from CaSki cervical carcinoma cells is described. The highest frequency of a cellular immune response in vitro to this antigen preparation was found in untreated patients with mild-to-moderate dysplasia (88%). The specificity of the cellular immune response in vitro to cervical carcinoma cellassociated antigens is clear from the low incidence of positive results as well as the low magnitude of individual responses in the group of patients with tumours unrelated to squamous cervical cell carcinoma and the group of healthy control donors: the maximal stimulation index observed in these groups was 9.6, whereas that in the patients with invasive cervical carcinoma or preinvasive stages was 48 (Tables I and II, Figure 1 ). The specificity of the response can also be concluded from the absence of stimulation by identically-prepared control antigens. As the same results were obtained with all control antigens it is unlikely that the results with CaSki supernatants are due to alloantigen stimulation. The lower incidences of cellular immunity to the CaSki antigen in the groups of cancer patients (macroinvasive squamous cell carcinoma of the uterine cervix or other tumours) may be ascribed to immunological anergy occurring in patients with advanced disease. However, (1) the results of (positive) PHA and recall-antigen stimulation in all groups, and (2) the absence of any relation between positive lymphocyte stimulation by CaSki antigen and by PHA or recall-antigen argues against this explanation of the results (illustrated for PHA in Table II) .
We have previously found the presence of antibody against cervical carcinoma cells mainly in patients with macroinvasive cancer ( Van de Linde et al., 1981) . In the present group of patients and controls essentially the same results were obtained (Table I ). There was no relation between the expression of a cellular immune response and the detection of antibody, even though both were putatively directed to antigens of cervical carcinoma cells (Figure 2 ). This makes possible interference by antibodies passively bound to mononuclear cell (sub)populations in the lymphocyte stimulation test unlikely. Inhibition by autologous serum has been noted by Vanky et al. (1975) in lymphocyte stimulation tests with autologous tumour cells in cancer patients. From our data we conclude that cellular immune reactivity and serum antibodies occur in our patients with apparent mutual exclusivity.
The highest frequency of cellular immune reactivity was found in the group of patients with preinvasive states (especially mild-to-moderate dysplasia), whereas the group of patients with macroinvasive stages of the tumour showed the highest incidence of serum antibodies. This divergence may be related to the in vivo role of cellular-and antibody-mediated immune reactions to tumour antigens (Cochran, 1978; DiSaia et al., 1972; Ioachim, 1976; Moore, 1978) . About twothirds of the patients with preinvasive stages of the tumour were positive in the lymphocyte stimulation test. A minority of these patients has been reported to develop invasive cervical carcinoma if untreated (about one third according to Noda et al., 1976) . In the context of the immunosurveillance theory it is tempting to suggest a relationship between the absence of cellular immune reactivity to the tumour and the progression of preinvasive lesions to invasive carcinoma. A possible role in vivo of tumour-directed antibodies in tumour enhancement has been hypothesized ( Van de Linde et al., 1981) . To test these hypotheses follow-up studies are needed; these are obviously impeded to the extent that all patients with preinvasive and invasive stages of cervical carcinoma receive treatment.
